DexCom, Inc. (NASDAQ:DXCM) SVP Patrick Michael Murphy sold 500 shares of the company’s stock in a transaction dated Thursday, January 9th. The shares were sold at an average price of $235.01, for a total transaction of $117,505.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Patrick Michael Murphy also recently made the following trade(s):

  • On Monday, December 9th, Patrick Michael Murphy sold 5,518 shares of DexCom stock. The shares were sold at an average price of $224.42, for a total transaction of $1,238,349.56.

Shares of DXCM traded down $1.97 during mid-day trading on Friday, hitting $237.30. 627,849 shares of the company’s stock were exchanged, compared to its average volume of 818,907. The company has a market cap of $21.72 billion, a price-to-earnings ratio of 791.00 and a beta of 0.76. DexCom, Inc. has a fifty-two week low of $107.44 and a fifty-two week high of $242.14. The company has a debt-to-equity ratio of 1.41, a quick ratio of 5.26 and a current ratio of 5.63. The stock’s 50-day moving average is $220.33 and its 200-day moving average is $174.83.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.45. The business had revenue of $396.30 million for the quarter, compared to analysts’ expectations of $348.99 million. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The business’s quarterly revenue was up 48.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 earnings per share. As a group, equities research analysts anticipate that DexCom, Inc. will post 1.34 EPS for the current year.

A number of research analysts have commented on DXCM shares. JPMorgan Chase & Co. upped their target price on shares of DexCom from $215.00 to $255.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. Stifel Nicolaus started coverage on shares of DexCom in a research report on Tuesday, October 22nd. They issued a “buy” rating and a $190.00 target price on the stock. Morgan Stanley upped their target price on shares of DexCom from $202.00 to $225.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 17th. Robert W. Baird upped their target price on shares of DexCom from $195.00 to $240.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, Zacks Investment Research raised shares of DexCom from a “hold” rating to a “buy” rating and set a $243.00 target price on the stock in a research report on Wednesday. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. DexCom has an average rating of “Buy” and an average price target of $209.80.

Several institutional investors and hedge funds have recently modified their holdings of the company. HWG Holdings LP lifted its position in shares of DexCom by 379.3% during the fourth quarter. HWG Holdings LP now owns 5,109 shares of the medical device company’s stock worth $1,118,000 after purchasing an additional 4,043 shares in the last quarter. Beck Bode LLC acquired a new stake in shares of DexCom during the third quarter worth about $1,571,000. Metropolitan Life Insurance Co NY lifted its position in shares of DexCom by 3.7% during the third quarter. Metropolitan Life Insurance Co NY now owns 6,673 shares of the medical device company’s stock worth $996,000 after purchasing an additional 236 shares in the last quarter. Orbimed Advisors LLC lifted its position in shares of DexCom by 46.1% during the third quarter. Orbimed Advisors LLC now owns 384,000 shares of the medical device company’s stock worth $57,308,000 after purchasing an additional 121,100 shares in the last quarter. Finally, Redmile Group LLC lifted its position in shares of DexCom by 76.7% during the third quarter. Redmile Group LLC now owns 304,158 shares of the medical device company’s stock worth $45,393,000 after purchasing an additional 132,058 shares in the last quarter. 98.21% of the stock is currently owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Municipal Bonds

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.